ProKid­ney's stock shoots high­er af­ter mixed Phase 2 da­ta

Kid­ney dis­ease drug de­vel­op­er ProKid­ney vault­ed above $1 per share this morn­ing, de­spite mixed open-la­bel Phase 2 da­ta.

The com­pa­ny is study­ing whether its lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER